CGTX Stock Summary and Trading Ideas (Cognition Therapeutics | NASDAQ:CGTX)

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Cognition Therapeutics trades on the NASDAQ stock market under the symbol CGTX.

As of March 20, 2026, CGTX stock price declined to $1.07 with 578,895 million shares trading.

CGTX has a beta of 1.99, meaning it tends to be more sensitive to market movements. CGTX has a correlation of 0.05 to the broad based SPY ETF.

CGTX has a market cap of $94.40 million. This is considered a Micro Cap stock.

In the last 3 years, CGTX traded as high as $3.83 and as low as $.22.

The top ETF exchange traded funds that CGTX belongs to (by Net Assets): VTI, VXF, IBRN.

CGTX has outperformed the market in the last year with a price return of +150.8% while the SPY ETF gained +16.6%. However, in the short term, CGTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -30.5% vs -4.4% return in SPY. But in the last 2 weeks, CGTX shares have fared better than the market returning +3.9% compared to SPY -3.3%.

CGTX support price is $1.03 and resistance is $1.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGTX shares will trade within this expected range on the day.